Clinical Evaluation of Cryoprecipitated Factor VIII
1967; American Medical Association; Volume: 199; Issue: 8 Linguagem: Inglês
10.1001/jama.1967.03120080088015
ISSN1538-3598
Autores Tópico(s)Platelet Disorders and Treatments
ResumoAlthough there is increasing reason to believe that the pathogenesis of classical hemophilia involves much more than deficiency of a plasma clotting factor, 1 treatment of bleeding episodes remains firmly based upon the infusion of factor VIII. 2 The rationale of plasma transfusion therapy has been well defined 3 and assay procedures 4,5 have been developed which permit an accurate diagnosis of hemophilia (hemophilia A), and, in addition, enable quantitative assessment of therapy. Nevertheless, treatment of this disorder still is beset with difficulties. Large and frequent transfusions of fresh, freshfrozen, or reconstituted freeze-dried plasma are required to achieve and maintain hemostatic levels of factor VIII. Daily transfusions approximating one third of the patient's circulating plasma volume are required over a period of weeks to control hemorrhage following surgical procedures. Such massive plasma transfusions present the concomitant risk of circulatory overload. Moreover, prolonged plasma therapy limits the mobility of the patient
Referência(s)